Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors

Nature Medicine

Volumn 9, Issue 5, 2003, Pages 568-574

  Taniguchi, Toshiyasu ^a   Tischkowitz, Marc ^a   Ameziane, Najim ^b   Hodgson, Shirley V ^a   Mathew, Christopher G ^a   Joenje, Hans ^b   Mok, Samuel C ^c   D'Andrea, Alan D ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; DRUG SENSITIVITY; FANCONI ANEMIA; FEMALE; GENE INACTIVATION; GENETIC STABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHUMAN; ONCOGENE; OVARY TUMOR; PHENOTYPE; PRIORITY JOURNAL; PROTEIN MODIFICATION; SIGNAL TRANSDUCTION;

CISPLATIN; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; FANCONI ANEMIA COMPLEMENTATION GROUP F PROTEIN; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; OVARIAN NEOPLASMS; RNA-BINDING PROTEINS; TUMOR CELLS, CULTURED;

EID: 0038075462     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm852     Document Type: Article

References (45)

1. Landis, S.H. et al. Cancer statistics, 1999. CA Cancer J. Clin. 49, 8-31 (1999).
2. Orth, K. et al. Genetic instability in human ovarian cancer cell lines. Proc. Natl. Acad. Sci. USA 91, 9495-9499 (1994).
3. Auersperg, N., Edelson, M.I., Mok, S.C., Johnson, S.W. & Hamilton, T.C. The biology of ovarian cancer. Semin. Oncol. 25, 281-304 (1998).
4. Harper, P., Marsh, D. & Zori, R, Current clinical practices for ovarian cancers. Semin. Oncol. 29, 3-6 (2002).
5. Husain, A. et al. Lisofylline sensitizes p53 mutant human ovarian carcinoma cells to the cytotoxic effects of cis-diamminedichloroplatinum (II). Gynecol. Oncol. 70, 17-22 (1998).
6. Joenje, H. & Patel, K.J. The emerging genetic and molecular basis of Fanconi anaemia. Nat. Rev. Genet. 2, 446-457 (2001).
7. Taniguchi, T. & D'Andrea, A.D. The Fanconi anemia protein, FANCE, promotes the nuclear accumulation of FANCC. Blood 100, 2457-2462 (2002).
8. Pace, P. et al. FANCE: the link between Fanconi anaemia complex assembly and activity. EMBO J21, 3414-3423 (2002).
9. Medhurst, A.L., Huber, P.A., Waisfisz, Q., de Winter, J.P. & Mathew, C.G. Direct interactions of the five known Fanconi anaemia proteins suggest a common functional pathway. Hum. Mol. Genet. 10, 423-429 (2001).
10. Garcia-Higuera, I. et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell 7, 249-262 (2001).
11. Taniguchi, T. et al. Convergence of the Fanconi anemia and ataxia telangiectasia signaling pathways. Cell 109, 459-472 (2002).
12. Howlett, N.G. et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297, 606-609 (2002).
13. Shimamura, A. et al. A novel diagnostic screen for defects in the Fanconi anemia pathway. Blood 100, 4649-4654 (2002).
14. de Winter, J.P. et al. The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM. Nat. Genet. 24, 15-16 (2000).
15. Esteller, M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21, 5427-5440 (2002).
16. Jones, P.A. & Laird, P.W. Cancer epigenetics comes of age. Nat. Genet. 21, 163-167 (1999).
17. Andrews, P.A. & Albright, K.D. Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. Cancer Res. 52, 1895-1901 (1992).
18. Krop, I.E. et al. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proc. Natl. Acad. Sci. USA 98, 9796-9801 (2001).
19. Provencher, D.M. et al. Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell. Dev. Biol. Anim. 36, 357-361 (2000).
20. Wilson, A.P. Characterization of a cell line derived from the ascites of a patient with papillary serous cystadenocarcinoma of the ovary. J. Natl. Cancer Inst. 72, 513-521 (1984).
21. Rahman, N. & Stratton, M.R. The genetics of breast cancer susceptibility. Annu. Rev. Genet. 32, 95-121 (1998).
22. Esteller, M. et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 92, 564-569 (2000).
23. Hedenfalk, I. et al. Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 344, 539-548 (2001).
24. Geisler, J.P., Hatterman-Zogg, M.A., Rathe, J.A. & Buller, R.E. Frequency of BRCA1 dysfunction in ovarian cancer. J. Natl. Cancer Inst. 94, 61-67 (2002).
25. Hilton, J.L. et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J. Natl. Cancer Inst. 94, 1396-1406 (2002).
26. Brown, R. et al. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 15, 45-52 (1997).
27. trathdee, G., MacKean, M.J., Illand, M. & Brown, R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18, 2335-2341 (1999).
28. Plumb, J.A., Strathdee, G., Sludden, J., Kaye, S.B. & Brown, R. Reversal of drug resistance in human tumor xenografts by 2-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 60, 6039-6044 (2000).
29. Fogh, J., Wright, W.C. & Loveless, J.D. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58, 209-214 (1977).
30. Hamilton, T.C. et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43, 5379-5389 (1983).
31. Hills, C.A. et al. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br. J. Cancer 59, 527-534 (1989).
32. Rauh-Adelmann, C. et al. Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines. Mol. Carcinog. 28, 236-246 (2000).
33. Kiguchi, K. et al. Selection of human ovarian carcinoma cells with high dissemination potential by repeated passage of the cells in vivo into nude mice, and involvement of Le(x)-determinant in the dissemination potential. Jpn. J. Cancer Res. 89, 923-932 (1998).
34. Schilder, R.J. et al. Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int. J. Cancer 45, 416-422 (1990).
35. Lewis, A.D., Hayes, J.D. & Wolf, C.R. Glutathione and glutathione-dependent enzymes in ovaran adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects. Carcinogenesis 9, 1283-1287 (1988).
36. Kupfer, G.M., Naf, D., Suliman, A., Pulsipher, M. & D'Andrea, A.D. The Fanconi anaemia proteins, FAA and FAC, interact to form a nuclear complex. Nat. Genet. 17, 487-490 (1997).
37. Yamashita, T., Barber, D.L., Zhu, Y., Wu, N. & D'Andrea, A.D. The Fanconi anemia polypeptide FACC is localized to the cytoplasm. Proc. Natl. Acad. Sci. USA 91, 6712-6716 (1994).
38. Timmers, C. et al. Positional cloning of a novel Fanconi anemia gene, FANCD2. Mol. Cell 7, 241-248 (2001).
39. Siddique, M.A., Nakanishi, K., Taniguchi, T., Grompe, M. & D'Andrea, A.D. Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells. Exp. Hematol. 29, 1448-1455 (2001).
40. Garcia-Higuera, I., Kuang, Y., Naf, D., Wasik, J. & D'Andrea, A.D. Fanconi anemia proteins FANCA, FANCC, and FANCG/XRCC9 interact in a functional nuclear complex. Mol. Cell. Biol. 19, 4866-4873 (1999).
41. Ory, D.S., Neugeboren, B.A. & Mulligan, R.C. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. USA 93, 11400-11406 (1996).
42. Kuang, Y. et al. Carboxy terminal region of the Fanconi anemia protein, FANCG/XRCC9, is required for functional activity. Blood 96, 1625-1632 (2000).
43. Naf, D., Kupfer, G.M., Suliman, A., Lambert, K. & D'Andrea, A.D. Functional activity of the Fanconi anemia protein FAA requires FAC binding and nuclear localization. Mol. Cell. Biol. 18, 5952-5960 (1998).
44. Yang, Y. et al. Targeted disruption of the murine Fanconi anemia gene, Fancg/Xrcc9. Blood 98, 3435-3440 (2001).
45. Herman, J.G., Graff, J.R., Myohanen, S., Nelkin, B.D. & Baylin, S.B. Methylationspecific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 93, 9821-9826 (1996).